These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Bruckert E; Giral P; Tellier P Circulation; 2003 Jul; 107(25):3124-8. PubMed ID: 12835406 [No Abstract] [Full Text] [Related]
8. Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention. Prescrire Int; 1999 Aug; 8(42):116-20. PubMed ID: 11503831 [TBL] [Abstract][Full Text] [Related]
10. Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Soveri I; Holdaas H; Jardine A; Gimpelewicz C; Staffler B; Fellström B Nephrol Dial Transplant; 2006 Aug; 21(8):2282-9. PubMed ID: 16574686 [TBL] [Abstract][Full Text] [Related]
11. [Reduction of cholesterol and myocardial infarction. Big differences between different groups when it comes to the therapeutic effect]. Håkansson J Lakartidningen; 1997 Dec; 94(49):4619, 4622-3. PubMed ID: 9445934 [No Abstract] [Full Text] [Related]
13. [Statins-a panacea?]. Klose G Z Kardiol; 2004; 93 Suppl 1():I19-22. PubMed ID: 15022003 [TBL] [Abstract][Full Text] [Related]
14. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046 [TBL] [Abstract][Full Text] [Related]
15. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292 [TBL] [Abstract][Full Text] [Related]
16. Cholesterol and violence: more questions than answers. Ernst E Br J Hosp Med; 1994 Apr 6-19; 51(7):329-30, 332-3. PubMed ID: 8081561 [No Abstract] [Full Text] [Related]
17. The South African Lipid Guidelines: is there a need for an update? Raal FJ; Schamroth C; Klug E; Mills P Cardiovasc J S Afr; 2004; 15(2):53-4. PubMed ID: 15148537 [No Abstract] [Full Text] [Related]
18. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Wilhelmsen L; Pyörälä K; Wedel H; Cook T; Pedersen T; Kjekshus J Eur Heart J; 2001 Jul; 22(13):1119-27. PubMed ID: 11428852 [TBL] [Abstract][Full Text] [Related]
19. Usefulness of lipid-lowering therapy in elderly patients. Wenger NK Am J Cardiol; 2002 Oct; 90(8):870-1. PubMed ID: 12372576 [No Abstract] [Full Text] [Related]
20. [Statins in secondary prevention of coronary heart disease]. Sandhofer F Wien Med Wochenschr; 1999; 149(5-6):125-8. PubMed ID: 10408003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]